XML 40 R10.htm IDEA: XBRL DOCUMENT

INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET	12 Months Ended
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET	INTELLECTUAL PROPERTY LITIGATION EXPENSES, NET The Company incurred intellectual property litigation expenses, including settlements and external legal costs, of $405.4 million, $33.4 million and $214.0 million during 2020, 2019 and 2018, respectively. On July 12, 2020, the Company reached an agreement with Abbott Laboratories and its direct and indirect subsidiaries ("Abbott") to, among other things, settle all outstanding patent disputes between the companies (the “Settlement Agreement”) in cases related to transcatheter mitral and tricuspid repair products. See Note 18 for additional information. The Settlement Agreement resulted in the Company recording an estimated $367.9 million pre-tax charge and related liability in June 2020 related to past damages. In addition, the Company will incur royalty expenses through May 2024 totaling an estimated $100 million. The Company made a one-time $100.0 million payment to Abbott in July 2020, and will make quarterly payments in future years. In January 2019, the Company reached an agreement with Boston Scientific Corporation ("Boston Scientific") to settle all outstanding patent disputes for a one-time payment to Boston Scientific of $180.0 million, which was included as an expense in 2018. The settlement covered alleged past damages and no further royalties will be owed by either party.